Simplify Logo

Full-Time

Senior Research Associate

Beta Islet

Posted on 6/20/2024

Sana Biotechnology

Sana Biotechnology

201-500 employees

Develops engineered cell therapies for diseases

Hardware
Biotechnology
Healthcare

Compensation Overview

$90k - $105kAnnually

Senior

Cambridge, MA, USA

Category
Lab & Research
Life Sciences
Requirements
  • BA/MA or MS in cell biology, stem cell biology, biotechnology, or a related field
  • Expertise in pluripotent stem cell cultures and directed differentiation techniques
  • Significant experiences in Flow cytometry, Immunocytochemistry, Microscopy, DNA/RNA isolation techniques
  • 2-3+ years of post-graduate academic or industry experience in pluripotent stem cell differentiations
  • Excellent interpersonal, organizational, and independent problem-solving skills
  • Proficiency with standard flow cytometry and imaging software
Responsibilities
  • Expands, maintains, and directs differentiation of pluripotent stem cells towards SC-islets
  • Cryopreserves pluripotent stem cells, SC-islets and intermediates
  • Executes in vitro molecular and cellular characterization assays (Flow cytometry, Immunocytochemistry, DNA/RNA isolation…etc)
  • Maintains excellent scientific documentations and contributes to SOP developments
  • Assuring compliance with all relevant lab safety and biosafety regulations

Sana Biotechnology develops engineered cells aimed at treating and potentially curing various diseases by addressing their root causes. Their approach involves repairing and controlling genes within cells or replacing damaged or missing cells, which can lead to new types of medicines that improve patient outcomes. The company primarily serves healthcare providers, research institutions, and pharmaceutical companies seeking advanced therapeutic solutions. Unlike many competitors, Sana focuses heavily on research and development of cellular therapies, monetizing their innovations through licensing agreements and partnerships. Their goal is to create effective treatments for a wide range of diseases, enhancing patient care and outcomes.

Company Stage

IPO

Total Funding

$865M

Headquarters

Seattle, Washington

Founded

2018

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-16%

2 year growth

-26%
Simplify Jobs

Simplify's Take

What believers are saying

  • Sana's recent FDA clearance for investigational new drug applications, such as SC262 and SC291, indicates promising progress in their clinical trials.
  • The company's ability to raise significant funds through PIPE offerings and public stock offerings demonstrates strong investor confidence and financial stability.
  • Expansion into key biotech hubs like Cambridge, MA, suggests growth opportunities and access to top-tier talent.

What critics are saying

  • The resignation of key executives like Dr. Douglas Williams could disrupt R&D momentum and strategic direction.
  • High competition in the biotechnology sector, especially in gene and cell therapy, may impact market share and revenue growth.

What makes Sana Biotechnology unique

  • Sana Biotechnology focuses on engineered cells to treat and potentially cure diseases at their genetic and cellular roots, setting it apart from traditional pharmaceutical approaches.
  • Their heavy investment in R&D and partnerships with pharmaceutical companies and research institutions provide a robust pipeline for innovative therapies.
  • Sana's hypoimmune platform, which aims to create cells that can 'hide' from the patient's immune system, is a unique technological advancement in the field.
INACTIVE